TLX300
/ Telix, Eli Lilly
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
April 02, 2025
Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma
(GlobeNewswire)
- "Telix Pharmaceuticals Limited...announces that a first patient has been dosed in the Phase 1 ZOLAR trial of TLX300-CDx (89Zr-olaratumab) in patients with advanced, metastatic soft tissue sarcoma (STS) at the Melbourne Theranostic Innovation Centre (MTIC) in Melbourne, Australia."
Trial status • Soft Tissue Sarcoma
December 19, 2024
ZOLAR: 89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma
(clinicaltrials.gov)
- P1 | N=50 | Recruiting | Sponsor: Telix Pharmaceuticals (Innovations) Pty Ltd | Not yet recruiting ➔ Recruiting | Initiation date: Aug 2024 ➔ Oct 2024 | Trial primary completion date: Dec 2025 ➔ Mar 2026
Enrollment open • Trial initiation date • Trial primary completion date • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • PDGFRA
August 05, 2024
ZOLAR: 89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma
(clinicaltrials.gov)
- P1 | N=50 | Not yet recruiting | Sponsor: Telix Pharmaceuticals (Innovations) Pty Ltd
New P1 trial • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • PDGFRA
April 17, 2023
Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical
(PRNewswire)
- "Telix Pharmaceuticals Limited...announces successful preclinical development of radiolabelled olaratumab, an antibody licensed from Eli Lilly and Company (Lilly). Telix has demonstrated proof-of-concept (PoC) of using olaratumab to selectively deliver both diagnostic and therapeutic radiation to tumours as a radiopharmaceutical moiety and has produced a candidate for clinical translation. Telix will now progress to first-in-human clinical studies based on these highly encouraging results.... Furthermore, olaratumab radiolabelled with therapeutic radionuclide payloads has demonstrated in vivo efficacy with significant reduction in tumour volumes in relevant disease models, even after administration of a single dose."
Preclinical • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor
1 to 4
Of
4
Go to page
1